

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

Aducanumab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During the scoping workshop it was noted that Alzheimer’s disease is more common in people with Down’s syndrome. However, people with Down’s syndrome were not included in the clinical trials.

The scoping workshop attendees also noted that there are also some differences in understanding of Alzheimer’s disease and dementia within different socio-economic groups. Those in higher socio-economic groups are likely to have better understanding of the disease and are more likely to access treatment.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Even though people with Down’s syndrome were excluded from the clinical trials, this is not an equalities issue since NICE recommendations will be for the population in the marketing authorisation which is not anticipated to exclude people with Down’s syndrome.

The committee will consider if its recommendations potentially disadvantage certain socioeconomic groups.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes were made to the draft scope to highlight any potential equality issues.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders related to potential equality issues were identified during the scoping process.

Approved by Associate Director (name): Ross Dent

Date: 1/07/2021